October 7, 2022 – Life sciences-focused search firm Slone Partners has placed Doug Lawrence as the new chief executive officer of Hygieia, a digital therapeutics company for insulin therapy. “Doug Lawrence is an extraordinarily driven and accomplished diabetes technology leader with a track record of tremendous success leading global business operations,” said Tara Kochis, president of Slone Partners. “He brings tremendous experience and a wealth of valuable knowledge to Hygieia and is well positioned to drive the company forward.”
“Doug has the perfect combination of experience and skill to shepherd Hygieia’s expansion in the United States and around the world,” said Eran Bashan, Hygieia co-founder and chairman of the board. “Now, with Doug serving as CEO, we will work together to build the nation’s leading network of diabetes clinics. The world of healthcare delivery is rapidly changing, and Doug’s leadership will allow us to accelerate our go-to-market plan. We are looking forward to partnering with others to simplify insulin therapy and improve outcomes.”
Mr. Lawrence brings three decades of medical technology leadership to his new role, including significant experience introducing products to market, restructuring and guiding companies through mergers and acquisitions, building global sales teams, raising venture capital, and overseeing operations. An experienced CEO, Mr. Lawrence has previously led three companies, including CeQur, which produces insulin patch pumps to treat type 2 diabetes. He also led the diabetes division at Becton Dickinson (now Embecta), a manufacturer of insulin syringes and pen needles.
With Hygieia, Mr. Lawrence will be responsible for leading operations, development, and global growth of the company and its d-Nav Insulin Management Program.
“Diabetes is a global epidemic imposing tremendous costs on patients and health systems,” said Mr. Lawrence. “Late stage, insulin-dependent diabetes can be incredibly challenging for patients and their medical partners to manage effectively. I’m thrilled to join this talented, passionate team whose proven, FDA-cleared d-Nav technology is poised to transform the safety and efficacy of insulin therapy and, in many cases, lower the overall cost of diabetes management. Hygieia delivers a scalable, autonomous digital therapy that enables physicians to automatically deliver individualized and daily customized insulin therapy for each of their patients with type 2 diabetes.”
Hygieia is the developer of d-Nav, the first FDA-cleared technology to autonomously adjust insulin doses directly to the patient. d-Nav’s AI-powered technology automatically interprets patient data and independently initiates insulin management. Hygieia is headquartered in Livonia, MI.
Proven Search Consultants
Slone Partners is a nationally recognized senior-level recruitment provider that specializes in delivering executive, management, and leadership talent for the diagnostic, biopharmaceutical, healthcare information technology, and laboratory testing industries. The firm has offices in Boston, New York, Washington, D.C., and San Francisco. Recently, Slone Partners was included among Hunt Scanlon Media’s “Top 50 Healthcare & Life Sciences Search Firms.”
Ms. Kochis joined the firm in 2004, bringing over a decade of healthcare experience. Her past sales career with industry leaders such as VERSYSS, American Medical Laboratories, and Quest Diagnostics covered a wide variety of healthcare segments, including information technology, medical records, and the diagnostic and laboratory testing industry. Prior to healthcare, Ms. Kochis recruited executive and management talent in the banking and finance sector.
Recent CFO Search
Slone Partners recently placed Brian Hogan as chief financial officer of InterVenn Biosciences. “Brian Hogan is an extremely smart and innovative financial executive with a track record of success throughout his career in the life sciences,” said Ms. Kochis, president of Slone Partners. “He brings energy, passion, and vision to the InterVenn leadership team as the company expands its footprint in the liquid biopsy, diagnostics, and healthcare space.” “I am delighted to welcome Brian to InterVenn as our CFO,” said Aldo Carrascoso, CEO of InterVenn. “The expansion of InterVenn’s executive leadership team with this critical new hire is a significant step forward toward our ability to take the company to the next level. With his extensive experience in the life sciences industry, Brian’s leadership within the financial function will be a driving force to scale our organization and help accelerate the growth of our innovative pipeline of liquid biopsy products and clinical solutions.”
Based in South San Francisco, CA, InterVenn Biosciences utilizes a proprietary glycoproteomic biomarker interrogation platform using AI and mass spectrometry for Next-Gen precision medicine.
Contributed by Scott A. Scanlon, Editor-in-Chief; Dale M. Zupsansky, Managing Editor; and Stephen Sawicki, Managing Editor – Hunt Scanlon Media